We are live on ! Find out more
KDNY

Chinook Therapeutics, Inc. Common Stock
KDNY

Delisted

KDNY was delisted on the 10th of August, 2023.

Back to rankings

77 hedge funds and large institutions have $366M invested in Chinook Therapeutics, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 26 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more capital invested

Capital invested by funds: $328M → $366M (+$38.4M)

0% more funds holding

Funds holding: 77 → 77 (0)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

38% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 26

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1M

Holders
77
Holders Change
–
Holders Change %
0%
% of All Funds
1.35%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
8
Increased
16
Reduced
26
Closed
8
Calls
–
Puts
$1M
Net Calls
-$1M
Net Calls Change
-$402K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$5.04M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.45M
3
AA
ALPS Advisors
Colorado
+$772K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$584K
5
Ensign Peak Advisors
Ensign Peak Advisors
Utah
+$548K

Top Sellers

Rank Fund Capital Flow
1
MIM
Monashee Investment Management
Massachusetts
-$4.33M
2
ABG
Ally Bridge Group
New York
-$3.17M
3
MAM
Marquette Asset Management
Minnesota
-$2.56M
4
SFM
Sphera Funds Management
Israel
-$1.63M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
ALSV
1
ATP Life Science Ventures
New York
$62.6M – – –
SB
2
Samsara BioCapital
California
$49.2M – – –
BlackRock
3
BlackRock
New York
$21.9M -$15.4K -946 -0.1%
EC
4
EcoR1 Capital
California
$19.4M – – –
O
5
OrbiMed
New York
$19.4M – – –
VC
6
Vivo Capital
California
$18.7M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$18.7M +$392K +24,031 +2%
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$18.2M +$4.45M +272,952 +30%
Fidelity Investments
9
Fidelity Investments
Massachusetts
$13.5M – – –
Baillie Gifford & Co
10
Baillie Gifford & Co
United Kingdom
$13.1M +$13.1K +801 +0.1%
BBA
11
Baker Bros. Advisors
New York
$11.6M – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$11.5M -$1.54M -94,244 -11%
RSCM
13
Rock Springs Capital Management
Maryland
$10.5M +$68.5K +4,200 +0.6%
SCM
14
Suvretta Capital Management
New York
$8.54M +$378K +23,160 +4%
Citadel Advisors
15
Citadel Advisors
Florida
$7.8M -$685 -42 -0%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$6.93M +$584K +35,817 +9%
Millennium Management
17
Millennium Management
New York
$6.36M +$5.04M +309,154 +308%
RCMNY
18
Rubric Capital Management (New York)
New York
$5.06M – – –
State Street
19
State Street
Massachusetts
$4.12M -$352K -21,557 -8%
EAM
20
Erste Asset Management
Austria
$3.21M +$254K +15,600 +8%
ACM
21
Altium Capital Management
New York
$3.2M – – –
Northern Trust
22
Northern Trust
Illinois
$2.93M -$175K -10,757 -5%
AG
23
Artal Group
Luxembourg
$2.81M – – –
AAA
24
Affinity Asset Advisors
New York
$2.72M +$408K +25,000 +17%
Janus Henderson Group
25
Janus Henderson Group
United Kingdom
$2.7M – – –
1
2 3 4

KDNY Hedge Fund Activity: Q1 2021 in Review

77 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q1 2021, worth a combined $366M — up 12% from $328M a quarter earlier.

Fund positioning in KDNY was balanced in Q1 2021: 8 funds opened new positions, 8 closed out, 16 added to existing stakes and 26 trimmed.

The largest buyer was Millennium Management, adding an estimated $5.04M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $4.33M sold.

  • 77 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q1 2021, unchanged from Q4 2020.
  • Funds reported $366M of Chinook Therapeutics, Inc. Common Stock stock for Q1 2021, up 12% quarter-over-quarter.
  • 8 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q1 2021 and 8 closed out, a net change of 0 holders.
  • The largest Chinook Therapeutics, Inc. Common Stock buyer in Q1 2021 was Millennium Management, an estimated $5.04M added.
  • The largest Chinook Therapeutics, Inc. Common Stock seller in Q1 2021 was Monashee Investment Management, an estimated $4.33M sold.

Based on aggregated 13F filings for Q1 2021.